Cargando…
Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
No head-to-head trials have compared the efficacy and safety of nivolumab (Niv) plus ipilimumab (Ipi) combination therapy (Niv+Ipi) and existing regimens with immunotherapies approved as first-line treatment in patients with programmed cell death ligand 1 (PD-L1)-positive previously untreated advanc...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409193/ https://www.ncbi.nlm.nih.gov/pubmed/32679702 http://dx.doi.org/10.3390/cancers12071905 |
_version_ | 1783568009062776832 |
---|---|
author | Ando, Koichi Kishino, Yasunari Homma, Tetsuya Kusumoto, Sojiro Yamaoka, Toshimitsu Tanaka, Akihiko Ohmori, Tohru Ohnishi, Tsukasa Sagara, Hironori |
author_facet | Ando, Koichi Kishino, Yasunari Homma, Tetsuya Kusumoto, Sojiro Yamaoka, Toshimitsu Tanaka, Akihiko Ohmori, Tohru Ohnishi, Tsukasa Sagara, Hironori |
author_sort | Ando, Koichi |
collection | PubMed |
description | No head-to-head trials have compared the efficacy and safety of nivolumab (Niv) plus ipilimumab (Ipi) combination therapy (Niv+Ipi) and existing regimens with immunotherapies approved as first-line treatment in patients with programmed cell death ligand 1 (PD-L1)-positive previously untreated advanced non-small cell lung cancer (NSCLC). We conducted a network meta-analysis of four relevant Phase Ⅲ trials to compare the efficacy and safety of Niv+Ipi, pembrolizumab (Pem) plus platinum-based chemotherapy (PBC) (Pem+PBC), Pem, Niv, or PBC using Bayesian analysis. The primary efficacy endpoint was progression-free survival (PFS) in patients with advanced NSCLC with PD-L1 expression ≥1%. The primary safety endpoint was the incidence of Grade 3–5 drug-related adverse events (G3–5AEs). Efficacy and safety were ranked using surface under the cumulative ranking curve (SUCRA). With regard to PFS, Niv+Ipi was inferior to Pem+PBC, and superior to Pem, Niv, or PBC alone. SUCRA ranking showed Pem+PBC had the highest efficacy for PFS, followed by Niv+Ipi, Niv, PBC, and Pem. The safety outcome analysis revealed Niv+Ipi was generally well tolerated compared to existing immunotherapy regimens. These results provide clinical information regarding the efficacy and safety of Niv+Ipi and indicate the possibility of the Niv+Ipi combination as a new therapeutic option in PD-L1-positive advanced NSCLC. |
format | Online Article Text |
id | pubmed-7409193 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74091932020-08-26 Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis Ando, Koichi Kishino, Yasunari Homma, Tetsuya Kusumoto, Sojiro Yamaoka, Toshimitsu Tanaka, Akihiko Ohmori, Tohru Ohnishi, Tsukasa Sagara, Hironori Cancers (Basel) Review No head-to-head trials have compared the efficacy and safety of nivolumab (Niv) plus ipilimumab (Ipi) combination therapy (Niv+Ipi) and existing regimens with immunotherapies approved as first-line treatment in patients with programmed cell death ligand 1 (PD-L1)-positive previously untreated advanced non-small cell lung cancer (NSCLC). We conducted a network meta-analysis of four relevant Phase Ⅲ trials to compare the efficacy and safety of Niv+Ipi, pembrolizumab (Pem) plus platinum-based chemotherapy (PBC) (Pem+PBC), Pem, Niv, or PBC using Bayesian analysis. The primary efficacy endpoint was progression-free survival (PFS) in patients with advanced NSCLC with PD-L1 expression ≥1%. The primary safety endpoint was the incidence of Grade 3–5 drug-related adverse events (G3–5AEs). Efficacy and safety were ranked using surface under the cumulative ranking curve (SUCRA). With regard to PFS, Niv+Ipi was inferior to Pem+PBC, and superior to Pem, Niv, or PBC alone. SUCRA ranking showed Pem+PBC had the highest efficacy for PFS, followed by Niv+Ipi, Niv, PBC, and Pem. The safety outcome analysis revealed Niv+Ipi was generally well tolerated compared to existing immunotherapy regimens. These results provide clinical information regarding the efficacy and safety of Niv+Ipi and indicate the possibility of the Niv+Ipi combination as a new therapeutic option in PD-L1-positive advanced NSCLC. MDPI 2020-07-15 /pmc/articles/PMC7409193/ /pubmed/32679702 http://dx.doi.org/10.3390/cancers12071905 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ando, Koichi Kishino, Yasunari Homma, Tetsuya Kusumoto, Sojiro Yamaoka, Toshimitsu Tanaka, Akihiko Ohmori, Tohru Ohnishi, Tsukasa Sagara, Hironori Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis |
title | Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis |
title_full | Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis |
title_fullStr | Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis |
title_full_unstemmed | Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis |
title_short | Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis |
title_sort | nivolumab plus ipilimumab versus existing immunotherapies in patients with pd-l1-positive advanced non-small cell lung cancer: a systematic review and network meta-analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409193/ https://www.ncbi.nlm.nih.gov/pubmed/32679702 http://dx.doi.org/10.3390/cancers12071905 |
work_keys_str_mv | AT andokoichi nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis AT kishinoyasunari nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis AT hommatetsuya nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis AT kusumotosojiro nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis AT yamaokatoshimitsu nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis AT tanakaakihiko nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis AT ohmoritohru nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis AT ohnishitsukasa nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis AT sagarahironori nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis |